Document Detail


Neurocognitive outcome 12 months following cerebellar mutism syndrome in pediatric patients with medulloblastoma.
MedLine Citation:
PMID:  20713408     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The aim is to prospectively assess early neurocognitive outcome of children who developed cerebellar mutism syndrome (CMS) following surgical resection of a posterior fossa embryonal tumor, compared with carefully matched control patients. Children who were enrolled on an ongoing IRB-approved protocol for treatment of embryonal tumors, were diagnosed with postoperative CMS, and had completed prospectively planned neuropsychological evaluation at 12 months postdiagnosis were considered eligible. The cognitive outcomes of these patients were examined in comparison to patients without CMS from the same treatment protocol and matched with regard to primary diagnosis, age at diagnosis, and risk/corresponding treatment (n = 22 pairs). Seventeen were also matched according to gender, and 14 were also matched according to race. High-risk patients received 36-39.6 Gy CSI and 3D conformal boost to the primary site to 55.8-59.4 Gy. Average-risk patients received 23.4 Gy CSI and 3D conformal boost to the primary site to 55.8 Gy. Significant group differences were found on multiple cognitive outcomes. While the matched control patients exhibited performance in the average range, patients who developed CMS postsurgery were found to have significantly lower performance in processing speed, attention, working memory, executive processes, cognitive efficiency, reading, spelling, and math. Patients treated for medulloblastoma who experience postoperative CMS show an increased risk for neurocognitive impairment, evident as early as 12 months following diagnosis. This study highlights the need for careful follow-up with neuropsychological evaluation and for obtaining critical support for patients and their families.
Authors:
Shawna L Palmer; Tim Hassall; Karen Evankovich; Donald J Mabbott; Melanie Bonner; Cinzia Deluca; Richard Cohn; Michael J Fisher; E Brannon Morris; Alberto Broniscer; Amar Gajjar
Related Documents :
7760198 - One-year outcome following craniotomy for traumatic hematoma in patients with fixed dil...
6730018 - Early glottic cancer: surgery or radiation therapy?
9619998 - The chiari ii malformation: a surgical series.
10795888 - Cerebral arteriovenous malformations in children.
15371788 - Tethered cord in children: a clinical classification with urodynamic correlation.
18029518 - Is there still a place for emergency department thrombolysis following the introduction...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2010-08-16
Journal Detail:
Title:  Neuro-oncology     Volume:  12     ISSN:  1523-5866     ISO Abbreviation:  Neuro-oncology     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-18     Completed Date:  2011-03-18     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  100887420     Medline TA:  Neuro Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1311-7     Citation Subset:  IM    
Affiliation:
Department of Behavioral Medicine, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA. shawna.palmer@stjude.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Case-Control Studies
Cerebellar Diseases / etiology*,  pathology
Cerebellar Neoplasms / complications,  pathology,  therapy*
Child
Cisplatin / administration & dosage
Cognition Disorders / etiology*,  pathology
Combined Modality Therapy
Cranial Irradiation
Cyclophosphamide / administration & dosage
Female
Follow-Up Studies
Humans
Infratentorial Neoplasms / complications,  pathology,  therapy*
Male
Medulloblastoma / complications,  pathology,  therapy*
Mutism / etiology*
Neuropsychological Tests
Prospective Studies
Survival Rate
Time Factors
Treatment Outcome
Vincristine / administration & dosage
Grant Support
ID/Acronym/Agency:
P30CA21765/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
15663-27-1/Cisplatin; 50-18-0/Cyclophosphamide; 57-22-7/Vincristine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mode of action of hydrogen peroxide and other oxidizing agents: differences between liquid and gas f...
Next Document:  The polynuclear platinum BBR3610 induces G2/M arrest and autophagy early and apoptosis late in gliom...